Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd. has described CDK4/cyclin D1 inhibitors reported to be useful for the treatment of cancer.

Neushen Therapeutics Inc. has divulged NLRP3 inhibitors reported to be useful for the treatment of neurodegeneration.

Laekna Pharmaceutical Ningbo Co. Ltd. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Shanghai Xianxiang Medical Technology Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to an EGFR (HER1; erbB1) mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has disclosed camptothecin derivatives reported to be useful for the treatment of cancer.

Jiangsu Simcere Biologics Co. Ltd. has described bispecific antibody-drug conjugates (ADC) comprising a bispecific human antibody targeting hepatocyte growth factor receptor (HGFR; MET) and epidermal growth factor receptor (EGFR; HER1; erbB1), covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.

Signet Therapeutics Co. Ltd. has divulged transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer, metabolic disorders, inflammatory disorders and neurodegeneration.

Aché Laboratórios Farmacêuticos SA has identified compounds acting as sodium/glucose cotransporter 1 (SGLT-1), SGLT-2 and dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the treatment of cardiovascular, renal and metabolic diseases.

Laekna Pharmaceutical Ningbo Co. Ltd. has synthesized compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer.